Adjuvant AI Combined With Zoladex

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2008 by Fudan University
Sponsor:
Information provided by:
Fudan University
ClinicalTrials.gov Identifier:
NCT01352091
First received: May 10, 2011
Last updated: NA
Last verified: April 2008
History: No changes posted
  Purpose

The present study is a randomized open-label -phase III study that aims to compare the efficacy of Zoladex® combined with Aromidex® for 3-2 years after SERMs (tamoxifen and Fareston®) as an adjuvant therapy for 2-3 years with the efficacy of tamoxifen up to 5 years for premenopausal breast cancer women with hormone receptor positive, lymph node positive or tumor ≥4cm. According to St. Gallen's guideline, hormone receptor positive was defined as endocrine responsive and endocrine response uncertain categories (table 3-1), and only those with ER or PR expression undetectable were considered as HR negative. The pathological evaluation of axillary lymph node could be done by sentinel node biopsy (SNB) when axillary nodes were clinically impalpable accompanied with axillary lymph node dissection (ALND) or directly through ALND when axillary nodes appeared to be positive in clinical examination. Based on the operating standard of local medical institution, identifying the numbers of lymph nodes to do the pathological evaluation and to do the dissection of I- or II-station nodes accurately.


Condition Intervention Phase
Breast Cancer
Drug: Zoladex+AI
Drug: TAM
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized ,Open Label Study Comparing the Efficacy of Zoladex® Combined With Arimidex® for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor≥ 4cm.

Resource links provided by NLM:


Further study details as provided by Fudan University:

Primary Outcome Measures:
  • DFS [ Time Frame: 5 Years ] [ Designated as safety issue: No ]
    Disease free survival (DFS): DFS related events ware defined as local recurrence, distant metastasis, secondary primary cancer or death, whichever occurred first.during follow up


Secondary Outcome Measures:
  • OS [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Overall survival (OS)

  • Time to distant metastasis [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Time to distant metastasis

  • Bilateral secondary primary breast cancer morbidity [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Bilateral secondary primary breast cancer morbidity

  • DDFS [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Distant disease free survival (DDFS)

  • Osteoporosis related events [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Osteoporosis related events ( BMD and bone fracture incidence)

  • Other adverse events [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Other adverse events (Gynecological events, blood lipids, thrombosis, cardiovascular diseases, and etc.)


Estimated Enrollment: 670
Study Start Date: May 2008
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Switch to Zoladex + AI for 3-2 years
Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
Drug: Zoladex+AI
Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
Experimental: TAM
Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
Drug: TAM
Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must have signed and dated an informed consent form
  2. Patients must be female
  3. Primary invasive breast cancer pathologically approved by core needle or open biopsy
  4. Ipsilateral axillary or internal mammary nodes positive, or tumor size is equal to or larger than 4cm. Definition of nodes positive is according to the staging system of AJCC 6th edition (American Joint Cancer Commission) for breast carcinoma. The micrometastasis must be at least 0.2mm
  5. Patients must have undergone standard surgery for primary breast cancer as shown in the following:

    • a standard radical mastectomy or modified mastectomy
    • standard breast conservation surgery (BCS), which is lumpectomy or qaudrantectomy accompany with axillary dissection, and the surgical margins of the resected specimen must be negative. BCS must be followed by standardized adjuvant radiotherapy to the partial conserved breast (delivered after adjuvant chemotherapy completed)
    • Treatment for confirmed breast cancer including the surgery modality listed above, loco-regional radiotherapy after lumpectomy, adjuvant radiotherapy to the chest wall and/or internal mammary nodes and/or supraclavicular lymph nodes, adjuvant chemotherapy
  6. adjuvant endocrine therapy of TAM or Fareston must be started within 6 weeks when adjuvant chemotherapy or radiotherapy was finished
  7. The date of randomization must be processed after taking TAM or Fareston for 2 or more than 2 years, but not more than 3 years of time
  8. Patients taking neo-chemotherapy are eligible, and lymph node status could be identified during surgery before neo-adjuvant chemotherapy or after neo-adjuvant chemotherapy. The definition of lymph node positive is:

    • evaluation of lymph node status before neo-adjuvant chemotherapy must include pathological axillary nodes, internal mammary nodes (pN2b option) or supraclavicular nodes (pN3c option) involved. Micro-metastasis (i.e.≥0.2mm, pN1-pN3c) can be identified by the following method: fine needle aspiration (FNA) or sentinel node biopsy (SNB) or sampling/ total procedure of axillary dissection
    • patients with no nodes positive after neo-adjuvant chemotherapy, lymph node positive must be evaluated during surgery. Its definition was the either of following:

      • According the clinical practice guidelines of the local cancer center, it is acceptable when positive nodes was identified by SNB or axillary dissection
      • There is pathological evidence in lymph nodes positive (pN1-pN3c) during breast surgery after neo-adjuvant chemotherapy
  9. Patients diagnosed as occult breast cancer clinically are found to pathologically have primary invasive carcinoma or DCIS with micro-invasive lesion in ipsilateral breast, and primary lesion or axillary node metastasis express ER and/or PR positive
  10. Patients with synchronous bilateral cancers are eligible on the condition that If one side is IDC and the other side is DCIS, the IDC side should be of the ER and/or PR positive phenotype and IF two sides are both IDC, they must be ER and/or PR positive phenotype at the same time
  11. Hormone receptor positive (≥+) is defined as detecting ER or PR expression at any time is eligible. The situation of only PR positive and ER negative is eligible, too
  12. According to the standard operation principles for clinical practice of local cancer center, patients must be randomized within 4 weeks after definitive physical examination, imaging examination and laboratory testing show no evidence of recurrence or metastasis
  13. Based on the study objective, all patients are required to be premenopausal as defined by

    • menstruating actively
    • less than 6 months since last menstrual period (LMP), or patients younger than 40 years of age who became amenorrheic not more than 1 year if the serum free E2、FSH and LH level was premenopausal (according to the reference value of local center).
    • had previous hysterectomy with one or both ovaries left intact are eligible if the serum free E2、FSH and LH level are premenopausal (according to the reference value of local center).
  14. patients must have an ECOG performance status of 0 or 1 (0-fully active, able to carry on all pre-disease performance without restriction, 1-restricted in physical strenuous actively but ambulatory)
  15. leucocyte count must be ≥3.0*10^9/L and platelet count must be ≥100*10^9/L
  16. AST/SGOT or ALT/AGPT must be <3 times the ULN
  17. serum creatinine must be <2 times the ULN
  18. patients can swallow pills
  19. pregnancy testing is negative and are willing to do contraception during the treatment period

Exclusion Criteria:

  1. patients with metastatic malignant tumor
  2. previous history of asynchronous bilateral breast cancer
  3. any previous malignancy in the past 5 years, except for those treated with curative intent, such as carcinoma in situ of the cervix, squamous carcinoma of the skin or basal cell carcinoma of the skin
  4. any non-malignant systemic disease which interfere long time follow up
  5. history of medical ovarian ablation therapy
  6. history of AI therapy
  7. severe live dysfunction, Child-Pugh is grade C
  8. Occult breast cancer is found pathologically no IDC lesion or only DCIS without micro-invasive lesion in the ipsilateral breast
  9. patients with Her-2 overexpression had used, or is using, or intending to use adjuvant trastuzumab
  10. severe heart dysfunction, heart functional classification is above Class III Table 2 Child-Pugh score of hepatic cirrhosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01352091

Contacts
Contact: Zhi-min Shao, MD 86-021-64175590 ext 8808 zhimingshao@yahoo.com
Contact: Ya-jie Ji, MD 86-13818942254 jing_hong2008@yahoo.com.cn

Locations
China, Shanghai
FUSCC Recruiting
Shanghai, Shanghai, China, 200032
Contact: Zhi-min Shao, MD    86-021-64175590 ext 8808    zhimingshao@yahoo.com   
Sponsors and Collaborators
Fudan University
  More Information

No publications provided

Responsible Party: Fudan University Shanghai Cancer Center
ClinicalTrials.gov Identifier: NCT01352091     History of Changes
Other Study ID Numbers: CBCSG002
Study First Received: May 10, 2011
Last Updated: May 10, 2011
Health Authority: China: Food and Drug Administration

Keywords provided by Fudan University:
breast cancer
adjuvant endocrine therapy
AI
Zoladex

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Tamoxifen
Goserelin
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on August 28, 2014